Fulhold Pharma

Fulhold Pharma logo

Fulhold Pharma is a British pharmaceutical company.

History

Fulhold Pharma was incorporated in February 2014.[1]

The company's shares were admitted for trading on the GXG Market on 14 April 2015. Trading was suspended on 3 June 2015 at a price of 1.40 GBP and a market capitalisation of $108.9 million.[1][2][3] According to financial media group, MoneyWeb, the trading suspension was due to "fallout from the investigations into companies with links to Belvedere Management."[1] A June 2015 article in BizNews described the company as one of "four dubious British shell companies."[4] Shareholders include founding director David Cosgrove, who resigned in March 2015, as well as Dualstar Capital Private Equity Fund and the Alexander High Yield Fund.[1]

In August 2015, the company acquired Ful Hold Limited[1] which had worked on a topical drug for wounds with Euprotec in 2013.[5]

Products

Fulhold Pharma is a British pharmaceutical company with its manufacturing plant located in South Africa.[1] It manufactures carbohydrate derived fulvic acid as an ingredient in medications.[6]

Administration

A 2015 company press release listed David Squire as chief executive officer and chairman and Stephen Leivers as founder and chief scientific officer.[7]

See also

References

  1. 1 2 3 4 5 6 Cairns, Patrick Two listed companies connected to Brighton SPC suspended. Quote: "In the ongoing fallout from the investigations into companies with links to Belvedere Management, two British companies listed on Denmark’s GXG Markets exchange were suspended on Wednesday", Moneyweb, 9 June 2015. Retrieved 17 June 2015.
  2. ↑ Danish stock exchange suspends two Belvedere Group issuers. David Marchant, Offshore Alert, 4 June 2015. Retrieved 9 June 2015.
  3. ↑ Fulhold Pharma Plc. GXG Markets. Retrieved 9 June 2015.
  4. ↑ Another Belvedere limb severed as Cayman authorities take control of Brighton SPC. Alec Hogg, BizNews.com, 2 June 2015. Retrieved 17 June 2015. Quote: "an investigation by OffshoreAlert discovered that all or most of its “assets” comprise worthless shares in four dubious British shell companies that are listed on stock exchanges in Denmark, England and Germany. The companies are Eligere Investments Plc, Fulhold Pharma Plc"
  5. ↑ British firm's US Army deal for drug for wounded soldiers. James Hurley, The Telegraph, 15 April 2013. Retrieved 17 June 2015.
  6. ↑ Staff writer. "Company Profile". Bloomberg. Retrieved June 19, 2015.
  7. ↑ REG-Fulhold Pharma Plc: First Day of Dealing on GXG Main Quote - Press Release Reuters, 14 April 2015. Retrieved 9 June 2015.

External links

This article is issued from Wikipedia - version of the 2/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.